DOI: 10.1055/s-00000075

Seminars in Respiratory and Critical Care Medicine

References

Lundin J, Hagberg H, Repp R. , et al.
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.

Blood 2003;
101 (11) 4267-4272

Download Bibliographical Data

Search in:
Access:
Access: